SHANGHAI and CLINTON (NJ), November 4, 2024 – HuidaGene Therapeutics, a global clinical-stage biotechnology company focused on genome medicines, has achieved a groundbreaking milestone. The US FDA has cleared its investigational new drug (IND) application for HG202,...
We are witnessing a “golden age” for medicine, marked by breakthroughs in novel treatment modalities. While monoclonal antibodies (mAbs) have become routine, newer platforms like mRNA, antibody drug-conjugates (ADCs), and microbiome-based therapies are gaining...
Years of experiments and databases filled with RNA-seq results belie the simple reality that, until fairly recently, it was impossible to analyze RNA directly. The RNA-seq studies performed with conventional sequencing platforms are based entirely on cDNA, an...
The success of mRNA vaccines has sparked significant interest and investment in using mRNA technology to treat a broad range of diseases, including cancer, infectious diseases, and rare conditions. Yet when “naked” RNA is injected, it degrades quickly. To address this...
Wave Life Sciences has announced promising data from the RestorAATion-2 trial, marking the first clinical demonstration of RNA editing in humans. The phase 1b/2a study tests WVE-006, an RNA editing oligonucleotide, for the treatment of alpha-1 antitrypsin deficiency...
